UnitedHealth Group is the clear leader in the U.S. private health insurance market. Despite a challenging market environment, the company is up more than 7% today.
The main factor supporting the rally is a decision by the Centers for Medicare & Medicaid Services (CMS), which oversees the government program “Medicaid.” Medicaid is a type of U.S. government-subsidized health insurance intended for lower-income individuals—around 70 million Americans currently use the program.
Medicaid administrators decided to increase the program’s reimbursement rates. The increase amounted to 2.48%, which came in above sector analysts’ expectations. In practice, this means an expansion of insurers’ margins due to higher reimbursements from the U.S. government.
As a result, U.S. health insurers’ shares are experiencing euphoria, and bank analysts are rushing to update their valuations.
The market leader is up 7%, CVS Health is up nearly 5%, Alignment Healthcare is gaining more than 15%, and Evolent Health is rising 11%. Positive sentiment toward the sector is also reflected by Bank of America analysts, who have raised their price target for the company’s shares.
This news comes at a key moment for the company. After the close on April 7, the company is set to release its results for Q1 2026. The market expects EPS of around $6.65 per share and approximately $110 billion in revenue.
UNH.US (D1)
The company has been through a difficult period—its valuation is currently in the middle of a year-long consolidation channel following declines around the turn of 2024/2025. Will the Medicaid funding decision help the stock break out of consolidation? Source: xStation5
Gold surges 2% amid weakening US Dollar 📈
War-related shifts in the Forex market: USD plummets 💥; AUD, NZD and the CHF rebound 🚀
NZDUSD: hawkish RBNZ decision and TACO trade support the NZD 🚀
Oil plunges 10% 📉
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
